Zyclara Topical Cream 2.5pct Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Zyclara: Topical cream (2.5%)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png
Zyclara 2.5% Top Cream

What is this Medicine?

IMIQUIMOD (i mi KWI mod) cream is used to treat external genital or anal warts. It is also used to treat other skin conditions such as actinic keratosis and certain types of skin cancer.

Similar Brand Name Drugs : Aldara: Topical cream (5%)
Similar Generic Drugs : Imiquimod: Topical cream (5%)
CVS Pharmacy Patient Statistics for Zyclara: Topical cream(2.5%)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Zyclara 2.5% Topical Cream

NDC: 992070276
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Basal Cell Carcinoma, Condylomata Acuminata, Human Papillomavirus (HPV) Infection, Actinic Keratosis

Sometimes used for but not FDA approved for the following conditions:
Lentigo Maligna, Vulvar Intraepithelial Neoplasia (VIN), Herpes Simplex Virus Infection, Herpes Genitalis, Molluscum Contagiosum

Storage Information
Store upright
Protect from freezing
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Zyclara 2.5% Topical Cream

Reported Side Effects for Zyclara 2.5% Topical Cream

Vomiting Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Lightheadedness Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Cough Incidence:
<2.0%*
Severity: MILD
Onset: DELAYED
Nervousness Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Decreased Appetite Incidence:
<3.0%*
Severity: MILD
Onset: DELAYED
Fever Incidence:
<3.0%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Hair Loss Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Skin Irritation Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Joint Pain Incidence:
1.0-3.0%*
Severity: MILD
Onset: DELAYED
Irregular Heart Beat Incidence:
1.0%*
Severity: SEVERE
Onset: EARLY
Upset Stomach Incidence:
1.0-4.0%*
Severity: MILD
Onset: EARLY
Chest Pain Incidence:
1.0%*
Severity: MODERATE
Onset: EARLY
Back Pain Incidence:
1.0-4.0%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
1.0-3.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
1.0-2.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
1.0-4.0%*
Severity: MILD
Onset: EARLY
Infection Incidence:
1.0-15.0%*
Severity: MILD
Onset: DELAYED
Sore Throat Incidence:
1.0%*
Severity: MILD
Onset: DELAYED
Muscle Pain Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Inflammation Of The Lip Incidence:
2.0%*
Severity: MILD
Onset: DELAYED
Enlarged Lymph Nodes Incidence:
2.0-3.0%*
Severity: MODERATE
Onset: DELAYED
Eczema Vaccinatum Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Vesicular Rash Incidence:
2.0-9.0%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
2.0-8.0%*
Severity: MILD
Onset: EARLY
Sinus Infection Incidence:
2.0-7.0%*
Severity: MILD
Onset: DELAYED
Itching Incidence:
3.0-32.0%*
Severity: MILD
Onset: RAPID
Rhinitis Incidence:
3.0%*
Severity: MILD
Onset: EARLY
Skin Ulcer Incidence:
4.0-66.0%*
Severity: MODERATE
Onset: DELAYED
Skin Ulcer Incidence:
4.0-66.0%*
Severity: MODERATE
Onset: DELAYED
Skin Redness Incidence:
58.0-100.0%*
Severity: MODERATE
Onset: EARLY
Dry Skin Incidence:
88.0-93.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Zyclara

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5